Phase 1 Interim Analysis Blog Post

In this case study, we continue to work with the model and analysis from Immuno-modulation in Chronic Inflammation: Clinical Candidate Selection. We are targeting a membrane bound protein, which is...

Part 4: Consequences of Improper Data Collection Blog Post

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara discusses how improper data collection can extend timelines and incur additional cost.

Part 3: Ensuring Proper Data Collection Blog Post

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara touches on the burden associated with data collection.